Results 241 to 250 of about 17,427,068 (314)

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Correction: Evaluating preoperative risk factors for deep vein thrombosis in elderly patients with hip fractures and chronic kidney disease: a retrospective study. [PDF]

Eur J Med Res
Jia R, Men X, Ran F, Li X, Long Y.
europepmc   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Pathways to Clinical Training Opportunities for International Medical Students and IMGs: The California Experience. [PDF]

Ann Glob Health
Akey M, Groves B, Hudspeth JC, Rabin TL, Cortez S, Silvers R, Novotny J, Negussie F, Orozco P, Le P, Sawhney R, Raykar N, Arteaga M, Davis Rodriguez JA, Curran M, Byekwaso S, Saab F, Bandolin NS, Lipnick MS.   +18 more
europepmc   +1 more source

Library Holiday Hours; Public Library Access, Vol 9 (12) [PDF]

, 2011
Texas Medical Center Library
core   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Assessing changes in academic motivation across medical training stages: a longitudinal study in Malaysia. [PDF]

Ann Med
Aziz CR, Mohd Noor MN, Ibrahim MF, Lin GSS, Azhary JMK, Lye AJ, Vadivelu J, Foong CC.   +7 more
europepmc   +1 more source

Lecture and Book Signing by Dr. Peter Hotez; Keep Your Copyright! New Class Offered at the Library, Vol 10 (8) [PDF]

, 2012
Texas Medical Center Library
core   +1 more source

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database

, 2019
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, C. Esnault, Yujin Shuto, Hiroshi Maegawa, Daisuke Koya   +8 more
openalex   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source